Novel endocrine therapies: What is next in estrogen receptor positive, HER2 negative breast cancer?

Corti, C; De Angelis, C; Bianchini, G; Malorni, L; Giuliano, M; Hamilton, E; Jeselsohn, R; Jhaveri, K; Curigliano, G; Criscitiello, C

Criscitiello, C (通讯作者)，European Inst Oncol, Div Early Drug Dev Innovat Therapies, Via Ripamonti 435, I-20141 Milan, Italy.

CANCER TREATMENT REVIEWS, 2023; 117 ():

Abstract

Endocrine therapy (ET) is the cornerstone of management in hormone receptor (HR)+ breast cancer (BC). Indeed, targeting the estrogen receptor (ER) sig......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索